Long-term persistence of RBD+ memory B cells encoding neutralizing antibodies in SARS-CoV-2 infection

SARS-CoV-2感染中编码中和抗体的RBD+记忆B细胞的长期存在

阅读:7
作者:Arunasingam Abayasingam,Harikrishnan Balachandran,David Agapiou,Mohamed Hammoud,Chaturaka Rodrigo,Elizabeth Keoshkerian,Hui Li,Nicholas A Brasher,Daniel Christ,Romain Rouet,Deborah Burnet,Branka Grubor-Bauk,William Rawlinson,Stuart Turville,Anupriya Aggarwal,Alberto Ospina Stella,Christina Fichter,Fabienne Brilot,Michael Mina,Jeffrey J Post,Bernard Hudson,Nicky Gilroy,Dominic Dwyer,Sarah C Sasson,Fiona Tea,Deepti Pilli,Anthony Kelleher,Nicodemus Tedla,Andrew R Lloyd,Marianne Martinello,Rowena A Bull

Abstract

Considerable concerns relating to the duration of protective immunity against severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) exist, with evidence of antibody titers declining rapidly after infection and reports of reinfection. Here, we monitor the antibody responses against SARS-CoV-2 receptor-binding domain (RBD) for up to 6 months after infection. While antibody titers are maintained, ∼13% of the cohort's neutralizing responses return to background. However, encouragingly, in a selected subset of 13 participants, 12 have detectable RBD-specific memory B cells and these generally are increasing out to 6 months. Furthermore, we are able to generate monoclonal antibodies with SARS-CoV-2 neutralizing capacity from these memory B cells. Overall, our study suggests that the loss of neutralizing antibodies in plasma may be countered by the maintenance of neutralizing capacity in the memory B cell repertoire.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。